Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Trial Profile

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 02 Apr 2025 According to a Mesoblast media release, the company provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor(rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation.
  • 26 Mar 2019 Status changed from active, no longer recruiting to completed, according to a Mesoblast media release.
  • 28 Dec 2018 According to a Mesoblast media release, based on the outcomes of this study, the company plans to meet with the FDA In the first half of 2019 to discuss a potential approval pathway for MPC-150-IM.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top